Licensing status

Publication and contact information


Hydroxyprostaglandin dehydrogenase 15 NAD (HPGD; 15-PGDH) expression as a biomarker of aspirin-associated decrease in colorectal cancer risk

Measuring HPGD expression could help predict whether regular aspirin use will help decrease colorectal cancer risk. In a study with 127,865 participants, regular aspirin use was associated with decreased incidence of colorectal cancer in subjects who had high HPGD expression in the colonic mucosa but not in subjects who had low HPGD expression. Next steps include carrying out a prospective clinical trial to determine whether levels of HPGD in patients are a significant predictor of whether aspirin therapy can decrease recurrent colorectal polyps.

SciBX 7(19); doi:10.1038/scibx.2014.572
Published online May 15, 2014

Use of HPGD to select individuals for treatment with aspirin patented; available for licensing

Fink, S.P. et al. Sci. Transl. Med.; published online April 23, 2014;
Contact: Andrew T. Chan, Harvard Medical School, Boston, Mass.
Contact: Reiko Nishihara,
Dana-Farber Cancer Institute,
Boston, Mass.
Contact: Sanford D. Markowitz, Case Western Reserve University, Cleveland, Ohio